The year in cardiology 2015: arrhythmias and device therapy
- PMID: 26726044
- PMCID: PMC5137382
- DOI: 10.1093/eurheartj/ehv725
The year in cardiology 2015: arrhythmias and device therapy
Conflict of interest statement
Potential Conflict of Interest J.S. has received consultant and/or speaker fees from Amgen, Astra-Zeneca, Atricure, Bayer, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cook Medical, Daiichi Sankyo, Medtronic, Pfizer, Sanofi-Aventis, Sorin, St Jude Medical, and Zoll. J.S. is co-director von CorXL. He reports grant support through his institution from Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, Medtronic, and St Jude Medical. G.H. has received research grants from Biotronik, Boston Scientific, and St Jude Medical through the University Leipzig/Heart Center. P.J. reports consultancy honoraria and lecture fees from Biosense Webster, St. Jude Medical, and Boston Scientific; he reports stock options for Cardio Insight.
Figures


Similar articles
-
The year in cardiology 2014: arrhythmias and device therapy.Eur Heart J. 2015 Feb 1;36(5):270-8. doi: 10.1093/eurheartj/ehu486. Epub 2015 Jan 2. Eur Heart J. 2015. PMID: 25559132 Review.
-
The year in clinical electrophysiology.J Am Coll Cardiol. 2005 Mar 1;45(5):790-5. doi: 10.1016/j.jacc.2005.01.001. J Am Coll Cardiol. 2005. PMID: 15734627 Review. No abstract available.
-
The Year in Cardiology 2016: arrhythmias and cardiac implantable electronic devices.Eur Heart J. 2017 Jan 21;38(4):238-246. doi: 10.1093/eurheartj/ehw629. Eur Heart J. 2017. PMID: 28043973 No abstract available.
-
Access to and clinical use of cardiac implantable electronic devices and interventional electrophysiological procedures in the European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm Association.Europace. 2016 Aug;18 Suppl 3:iii1-iii79. doi: 10.1093/europace/euw244. Europace. 2016. PMID: 27496955
-
The Year in Cardiology 2012: arrhythmia and pacing.Eur Heart J. 2013 Feb;34(5):333-7. doi: 10.1093/eurheartj/ehs451. Epub 2013 Jan 2. Eur Heart J. 2013. PMID: 23284092 Review.
References
-
- McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S, et al. A minimal or maximal ablation strategy to achieve pulmonary vein isolation for paroxysmal atrial fibrillation: a prospective multi-centre randomized controlled trial (the MINIMAX study) Eur Heart J. 2015;36(28):1812–1821. - PubMed
-
- Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S, et al. ADVICE trial investigators Adenosine-guided pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, randomised superiority trial. Lancet. 2015;386(9994):672–679. - PubMed
-
- Kobori A, Shizuta S, Inoue K, Kaitani K, Morimoto T, Nakazawa Y, et al. UNDER-ATP Trial Investigators Adenosine triphosphate-guided pulmonary vein isolation for atrial fibrillation: the unmasking dormant electrical reconduction by adenosine triphosphate (under-ATP) trial. Eur Heart J. 2015;36(46):3276–3287. - PubMed
-
- Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al. EAST-AF Trial Investigators Efficacy of antiarrhythmic drugs short-term use after catheter ablation for atrial fibrillation (EAST-AF) trial. Eur Heart J. 2016;37(7):610–618. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical